Clinical Trial Update: A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis) [Phase 2]

View source ↗

Summary

Phase II randomized, double-blind crossover study assessing pharmacokinetics, safety and tolerability of a liquid formulation of palivizumab (Synagis) in high-r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Synagis (palivizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: -Unhealthy Children With a History of Prematurity | Phase 2 | Status: COMPLETED